The president and chief executive officer of Satellos Bioscience provided an overview of the previously observed preclinical data supporting SAT-3247 as a potential therapy for muscular dystrophies. [WATCH TIME: 4 minutes]
Frank Gleeson
Advertisement
Articles by Frank Gleeson
The president and chief executive officer of Satellos Bioscience provided insight on a new small molecule therapy, SAT-3247, in development for patients with muscular dystrophies. [WATCH TIME: 3 minutes]
Advertisement
Latest Updated Articles
Mechanism of Action of SAT-3247 in Muscular Dystrophy: Frank GleesonPublished: March 14th 2024 | Updated:
- Promising Preclinical Evidence of Skeletal Muscle Regenerator SAT-3247: Frank Gleeson
Published: March 26th 2024 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Interim ROSSINI Data Highlight Foslevodopa/Foscarbidopa’s Impact in Advanced Parkinson Disease
2
Inside the Phase 3 MASCOT Trial: Lundbeck’s Push for the First Disease-Modifying MSA Therapy
3
Phase 2 OPAL Study to Test Muscle-Targeting Therapy Apitegromab in Infants With SMA
4
FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related Amyloid Pathology
5
